Cagrilintide (10 Mg)

Cagrilintide activates amylin receptors (AMYRs) within the central nervous system, particularly in appetite-regulating regions such as the brainstem and hypothalamus. Through this pathway, it:   • Enhances satiety (you feel full sooner)   • Reduces hunger and food intake   • Slows gastric emptying, contributing to prolonged fullness   • Modulates reward-driven eating, decreasing cravings Unlike incretin therapies, its primary action is amylin-mediated, making it complementary to GLP-1–based agents.

  • Class: Amylin analogue (peptide)   • Duration: Long-acting (designed for infrequent dosing in research settings)   • Central Effect: Appetite suppression without direct insulin secretion   • Peripheral Effect: Delayed gastric emptying

Cagrilintide has been investigated for weight management and obesity due to its strong effects on appetite control. Research has shown additive or synergistic weight-loss effects when combined with GLP-1 receptor agonists, highlighting its role as a satiety amplifier rather than a glycemic driver.